At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 1,800 enrolled
Drug / intervention
VAQTA® +1 morebiological
Likely dose
VAQTA® 0.5 mlfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open, Multicenter Study of the Safety and Tolerability of VAQTA(TM) and ProQuad(TM) in Healthy Children 12 to 23 Months of Age
In Brief
A Phase 4 clinical trial evaluating VAQTA® and ProQuad for Hepatitis A and 4 related conditions. Completed, enrolled 1,800 participants.
Detailed Summary
Two doses each of Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella \[Oka/Merck\] Virus Vaccine Live will be given concomitantly or non-concomitantly. Safety data will be collected following each vaccination.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatitis A, Measles, Mumps, Rubella, Chickenpox
Countries--
Collaborators--
Timeline
Phase 4CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 2006
Enrollment StartMar 2007
Primary CompletionJan 2008
TodayJul 2026
First PostedMay 16, 2006
Enrollment StartMar 26, 2007
Primary CompletionJan 15, 2008
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 20.1 years ago
Interventions
VAQTA®biological
0.5 ml injection VAQTA®; 2nd 0.5 ml injection VAQTA® 24 week period of treatment.
ProQuadbiological
0.5 ml injection ProQuad; 2nd 0.5 ml injection ProQuad®. 24 week period of treatment.